According to the complaint, Cormier experienced severe symptoms, including lethargy and minimal responsiveness, after taking Glenmark’s pills. When she was taken to MaineHealth Maine Medical Center’s emergency department, blood tests revealed alarmingly high potassium levels, so extreme that the medical staff ordered retests to confirm their accuracy. Tragically, Cormier was transferred to hospice care and died shortly thereafter.
Glenmark $50M Suit : Recall and Alleged Negligence
The complaint points to a Class I recall of 46 million of Glenmark’s potassium chloride capsules that began on May 30, 2024. A Class I recall is the FDA’s most serious type, issued when there is a reasonable probability that the use of a product will cause severe adverse health consequences or death. However, Butler alleges that Glenmark waited an additional month before warning patients, by which time her mother had already taken the pills that led to her death in June.
Butler asserts that her mother’s death could have been avoided if Glenmark had not sold the defective drugs or had promptly alerted patients to the risks. The lawsuit also raises concerns about other batches of the potassium chloride pills, noting that they are under a Class II recall, and highlights Glenmark’s history of pulling products from the market due to contamination issues.
Seeking Justice and Accountability
Butler seeks to represent a class of all U.S. residents who purchased Glenmark’s potassium chloride pills, arguing that the capsules are worthless due to their dangerous nature. The lawsuit seeks full refunds for these buyers, along with damages for any injuries caused by the pills.
